Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma—a European multicenter cohort

Pomej, Katharina; Balcar, Lorenz; Shmanko, Kateryna; Welland, Sabrina; Himmelsbach, Vera; Scheiner, Bernhard; Mahyera, A.; Mozayani, B.; Trauner, Michael; Finkelmeier, Fabian; Weinmann, Arndt; Vogel, Arndt; Pinter, Matthias

doi:10.1016/j.esmoop.2023.100783

Cited by 7 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This patient harbored a stable disease at imaging under AB treatment with a PFS of 7.8 months 15 . Recently a series of seven patients who received immunotherapy was described, of these only three received atezolizumab plus bevacizumab, the median OS from the start of immunotherapy for all patients was 17.8 months 16 . A Korean study retrospectively examined the efficacy and safety of ICIs in 25 cHCC‐CCA patients.…”

Section: Discussionmentioning

confidence: 99%

“…Data about immunotherapy and cHCC‐CCA in the literature relies mostly on two case reports and a small case series. 14 , 15 , 16 The first case report presents a patient with metastatic cHCC‐CCA treated by pembrolizumab as a third‐line treatment after sorafenib and regorafenib. This patient experienced a complete radiological response persistent after 18 months of immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…15 Recently a series of seven patients who received immunotherapy was described, of these only three received atezolizumab plus bevacizumab, the median OS from the start of immunotherapy for all patients was 17.8 months. 16 -435 mostly treated with nivolumab monotherapy and that all but one of the included patients had been previously treated with other types of chemotherapy. 23 In the current study, we showed that AB was associated with a median PFS of 3 months and median OS of 13 months in patients treated in the first line.…”

Section: Variablesmentioning

confidence: 99%

“…To date, only few case reports describe the use of immunotherapies (including one with AB in third line) in patients with cHCC‐CCA 14,15 . Recently, three patients affected by cHCC‐CCA treated with AB were reported in a multicentric series 16 . On the other hand, immunotherapy with durvalumab in combination with standard chemotherapy has recently demonstrated its efficacy in CCA 17 …”

Section: Introductionmentioning

confidence: 99%

“… 14 , 15 Recently, three patients affected by cHCC‐CCA treated with AB were reported in a multicentric series. 16 On the other hand, immunotherapy with durvalumab in combination with standard chemotherapy has recently demonstrated its efficacy in CCA. 17 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Atezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study

Gigante,

Bouattour,

Bedoya

et al. 2023

UEG Journal

View full text Add to dashboard Cite

BackgroundsThe efficacy of atezolizumab/bevacizumab has never been reported in patients with metastatic/unresectable combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA).Patients and MethodsWe retrospectively included patients with a histological diagnosis of unresectable/metastatic cHCC‐CCA and treated with atezolizumab/bevacizumab (2020–2022) in 7 centers. Clinical and radiological features were collected at the beginning of atezolizumab/bevacizumab. We reported the radiological response using RECIST criteria, overall survival (OS) and progression‐free survival (PFS).ResultsSixteen patients with cHCC‐CCA were included and were predominantly male (75%) with advanced fibrosis/cirrhosis (69%). Nine patients received atezolizumab/bevacizumab as a first‐line systemic treatment, 5 as a second line, 1 as a third line and 1 as a fifth line. Severe digestive bleeding occurred in 2 patients. Among the 9 patients treated in the first line, 4 experienced radiological progression, 3 partial response and 1 had stable disease. Patients treated with atezolizumab/bevacizumab in the first line had a median OS of 13 months and a median PFS of 3 months. Among the 7 patients receiving atezolizumab/bevacizumab as a second line or more, 4 patients harbored a stable disease, 2 a partial response, and 1 a progressive disease.ConclusionsThe combination of atezolizumab and bevacizumab showed signs of anti‐tumor efficacy in patients with unresectable/metastatic cHCC‐CCA.

show abstract

Section: Discussionmentioning

confidence: 99%